Cargando…
Costs of treating multidrug-resistant TB in California in 2022
Autores principales: | Katrak, S., Wang, R., Barry, P. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
International Union Against Tuberculosis and Lung Disease
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10599414/ https://www.ncbi.nlm.nih.gov/pubmed/37880888 http://dx.doi.org/10.5588/ijtld.23.0150 |
Ejemplares similares
-
1881. Costs of Treating Multidrug Resistant Tuberculosis in California, 2022
por: Katrak, Shereen, et al.
Publicado: (2023) -
Laboratory costs of diagnosing TB in a high multidrug-resistant TB setting
por: Cates, L., et al.
Publicado: (2021) -
Sputum culture conversion definitions and analytic practices for multidrug-resistant TB
por: Rodriguez, C. A., et al.
Publicado: (2021) -
Bedaquiline for multidrug-resistant tuberculosis and QTc prolongation in California
por: Katrak, Shereen, et al.
Publicado: (2021) -
VIDAS(®) TB-IGRA reagents induce a CD4+ and CD8+ T-cell IFN-γ response for both TB infection and active TB
por: Petruccioli, E., et al.
Publicado: (2022)